Mario Sznol, MD

Articles

Dr. Sznol on the Significance of the Relatlimab/Nivolumab Approval in Metastatic Melanoma

July 26th 2022

Mario Sznol, MD, explains the evaluation of efficacy and safety when examining the benefits of new immunotherapy combinations in cancer.

Dr. Sznol on the Multidisciplinary Management of Immunotherapy-Associated Toxicities in Melanoma

January 11th 2021

Mario Sznol, MD, Yale Cancer Center, discusses the multidisciplinary management of toxicities associated with immunotherapy in patients with melanoma.

Dr. Sznol on Toxicities Associated With Immunotherapy in Melanoma

January 7th 2021

Mario Sznol, MD, discusses toxicities associated with immunotherapy in patients with melanoma.

Dr. Sznol on the Challenges of Managing Immune-Related Toxicities in Melanoma

December 16th 2020

Mario Sznol, MD, discusses the challenges of managing immune-related toxicities in melanoma.

Dr. Sznol on the Use of Immunotherapy in Melanoma

May 22nd 2020

Mario Sznol, MD, discusses the use of immunotherapy in melanoma.

Dr. Sznol on the Use of Immunotherapy in Melanoma

May 21st 2020

Mario Sznol, MD, discusses the use of immunotherapy in melanoma.

Dr. Sznol on Immune-Related Toxicities in Melanoma

January 11th 2020

Mario Sznol, MD, discusses the adverse events that can occur from nivolumab in combination with ipilimumab for patients with melanoma.

Dr. Sznol on Managing Patients Beyond Initial Treatment in Melanoma

January 3rd 2020

Mario Sznol, MD, discusses the management of patients with melanoma who progress on immune checkpoint inhibitors.

Dr. Sznol Discusses the Combination of Ipilimumab and Nivolumab in Melanoma

September 11th 2019

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the benefits of immunotherapy, specifically the combination of the CTLA-4 inhibitoripilimumab and the PD-1 inhibitor nivolumab, in melanoma.

Dr. Sznol on Factors to Consider When Combining VEGF TKIs/Immunotherapy in RCC

May 22nd 2019

Mario Sznol, MD, professor of medicine, co-director, Cancer Immunology Program, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses factors to consider when combining VEGF TKIs with immunotherapy in renal cell carcinoma (RCC).

Dr. Sznol on Patient Selection for Combination Therapy in mRCC

May 9th 2019

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses patient selection for combination therapy in metastatic renal cell carcinoma.

Dr. Sznol on Unanswered Questions With Immunotherapy in RCC

March 22nd 2019

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses unanswered questions with immunotherapy in the treatment of patients with renal cell carcinoma.

Dr. Sznol Discusses Immunotherapy in Non-Clear Cell Renal Cancer

September 6th 2018

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses immunotherapy in non-clear cell renal cancer.

Dr. Sznol Discusses Immunotherapy Combinations in RCC

June 1st 2018

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses immunotherapy combinations in renal cell carcinoma.

Dr. Sznol Discusses the Importance of Clinical Trials in RCC

May 22nd 2018

Mario Sznol, MD, professor of Medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the importance of clinical trials in renal cell carcinoma.

Dr. Sznol Discusses Advancements in Immunotherapy for RCC

March 24th 2018

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses advancements in immunotherapy for the treatment of patients with renal cell carcinoma.

Dr. Sznol Discusses the Role of Surgery in Melanoma

December 8th 2017

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the role of surgery in the treatment of patients with melanoma.

Dr. Sznol on Immunotherapy in Patients With RCC

March 19th 2016

Mario Sznol, MD, professor of Medicine, Yale Cancer Center, shares how to discuss immunotherapy as a treatment option for patients with renal cell carcinoma (RCC).

Dr. Sznol on Managing Toxicities in Treatment of Melanoma

April 15th 2015

Mario Sznol, MD, professor of medicine (medical oncology), clinical research program leader, Melanoma Program, Yale Cancer Center, discusses how to manage toxicities in treatment of melanoma.

Dr. Sznol on Combining Nivolumab and Ipilimumab for the Treatment of Advanced Melanoma

June 10th 2014

Mario Sznol, MD, professor, Internal Medicine, Yale Cancer Center, discusses a phase I trial that examined the combination of nivolumab and ipilimumab for the treatment of advanced melanoma.